Aprea Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-04-17$1.00 RISE2026-05-19$0.80 PEAK2026-05-22$0.95 35d | -20.0% 32d | Missed | Missed | — | — | +18.8% 3d | Missed |
DROP2025-11-28$1.26 RISE2026-03-25$0.67 PEAK2026-04-17$1.00 140d | -46.7% 117d | Missed | Missed | — | — | +49.0% 23d | Missed |
DROP2025-10-20$1.65 RISE2026-01-29$0.59 PEAK2026-04-17$1.00 179d | -64.2% 101d | Missed | Missed | — | — | +69.5% 78d | Missed |
DROP2025-07-22$2.08 RISE2025-09-24$1.42 PEAK2025-10-20$1.65 90d | -31.7% 64d | Missed | Missed | — | — | +16.2% 26d | Missed |
DROP2025-02-14$3.59 RISE2025-06-23$1.60 PEAK2025-07-22$2.08 158d | -55.4% 129d | Missed | Missed | — | — | +30.0% 29d | Missed |
DROP2025-01-06$4.30 RISE2025-04-21$1.47 PEAK2025-06-04$1.94 149d | -65.8% 105d | Missed | Missed | — | — | +32.0% 44d | Missed |
DROP2024-10-17$4.45 RISE2024-11-22$2.88 PEAK2025-01-06$4.30 81d | -35.3% 36d | Missed | Missed | — | — | +49.3% 45d | Missed |
DROP2024-06-04$4.78 RISE2024-10-10$2.54 PEAK2024-10-17$4.45 135d | -46.9% 128d | Missed | Missed | — | — | +75.2% 7d | Missed |
DROP2024-04-03$6.67 RISE2024-08-12$3.22 PEAK2024-10-17$4.45 197d | -51.7% 131d | Missed | Missed | — | — | +38.2% 66d | Missed |
DROP2024-02-29$8.46 RISE2024-03-14$5.31 PEAK2024-03-19$6.74 19d | -37.2% 14d | Missed | Missed | — | — | +26.9% 5d | Missed |
DROP2023-10-17$5.33 RISE2023-10-31$3.36 PEAK2024-01-09$6.22 84d | -37.0% 14d | Missed | Missed | — | — | +85.1% 70d | Missed |
DROP2023-03-03$5.25 RISE2023-07-10$2.89 PEAK2023-09-20$4.35 201d | -45.0% 129d | Missed | Missed | — | — | +50.7% 72d | Missed |
DROP2022-10-14$15.20 RISE2023-02-13$0.47 PEAK2023-02-14$8.20 123d | -96.9% 122d | Missed | Missed | — | — | +1630.0% 1d | Missed |
DROP2022-08-10$19.92 RISE2022-12-16$6.40 PEAK2023-01-17$11.14 160d | -67.9% 128d | Missed | Missed | — | — | +74.1% 32d | Missed |
DROP2022-07-19$25.00 RISE2022-09-30$13.00 PEAK2022-10-14$15.20 87d | -48.0% 73d | Missed | Missed | — | — | +16.9% 14d | Missed |
1–15 / 28 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Aprea Therapeutics Inc: Aprea Therapeutics - files for resale of up to 5.5 million shares by selling stockholders - SEC filing...
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $7 to $6.
Aprea Therapeutics (APRE) reports Q1 2026 results with a narrow EPS beat, strong $46.5M cash position, and promising APR-1051 clinical data ahead of ASCO 2026.
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. This is a 66.67 percent increase over losses of $(0.66) per share from
Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051Two partial responses observed with continued encouraging tolerability in the...
Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst calls
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts view APRE, SRFM, CNH stocks.
Oppenheimer analyst Matthew Biegler initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Outperform rating and announces Price Target of $5.
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined
DOYLESTOWN, Pa., April 21, 2026 -- Aprea Therapeutics, Inc. , a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with...
Wedbush analyst Robert Driscoll reiterates Aprea Therapeutics (NASDAQ:APRE) with a Outperform and maintains $7 price target.
HC Wainwright & Co. analyst Joseph Pantginis maintains Aprea Therapeutics (NASDAQ:APRE) with a Buy and lowers the price target from $4 to $1.2.
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 5.61 percent. This is a 34.69 percent increase over losses of $(0.49) per share
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| APRE | +9.17% | +0.90% | +4.69% | -48.68% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +6.20% | +6.62% | +8.13% | -61.37% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 25.1K | $19.15K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-13 | -0.23 | -0.22 | +4.35% |
| 2026-03-16 | -0.36 | -0.32 | +11.11% |
| 2025-11-12 | -0.10 | -0.47 | -370.00% |
| 2025-08-12 | -0.71 | -0.53 | +25.35% |
| 2025-03-25 | -0.54 | -0.49 | +9.26% |
| 2024-11-07 | -0.74 | -0.64 | +14.09% |
| 2024-08-12 | -0.60 | -0.58 | +4.13% |
| 2024-05-14 | -0.80 | -0.67 | +16.25% |
| 2024-03-26 | -0.93 | -0.92 | +1.08% |
| 2023-11-09 | -1.04 | -0.86 | +17.31% |
| 2023-08-10 | -1.38 | -0.87 | +36.96% |
| 2023-05-15 | -0.82 | -1.34 | -63.41% |
| 2023-03-30 | -2.50 | -0.92 | +63.20% |
| 2022-11-09 | -1.60 | -2.40 | -50.00% |
| 2022-08-11 | -6.20 | -19.63 | -216.55% |